{
    "2020-02-18": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Mylan-Upjohn merger filings contemplate coronavirus impact",
                "features": {
                    "keywords": [
                        "Mylan-Upjohn",
                        "merger",
                        "filings",
                        "coronavirus",
                        "impact"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie's $63 Billion Allergan Takeover Is Looming — Is It Time To Add Shares?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Allergan",
                        "Takeover",
                        "Billion"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Triangle's big slice of NC bio/pharma pie – List Insights",
                "features": {
                    "keywords": [
                        "Triangle",
                        "NC",
                        "bio/pharma",
                        "insights"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biopharma"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",
                "features": {
                    "keywords": [
                        "European Commission",
                        "Approves",
                        "VYNDAQEL®",
                        "Transthyretin",
                        "Amyloid",
                        "Cardiomyopathy",
                        "ATTR-CM"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}